Filing Summary
Entity note: The request identifies Profusa, Inc., but the supplied filing is NorthView Acquisition Corp.’s Form 10-K. This summary covers NorthView, not Profusa.
Business context and reporting period
NorthView is a blank-check company formed on April 19, 2021 to pursue a business combination. It stated an intended focus on healthcare innovation, including biopharmaceuticals, medical technology, diagnostics and related services, but had not selected a target by December 31, 2021. The reporting period is from inception through December 31, 2021; the company completed its IPO on December 22, 2021.
Financial performance, cash flow and liquidity
- Revenue and operations: No operating revenue or operating activity had begun. The company expects operating revenue only after a business combination, if any.
- Net income: $300,433 for the inception-to-year-end period, comprising $597,567 gain from remeasuring warrant liabilities and $6,461 trust-account interest, offset by $45,047 formation and operating costs and $258,548 of offering costs allocated to warrants. Basic and diluted earnings per share were $0.06.
- Cash and trust assets: At year-end, cash was $741,228 and cash and marketable securities in the trust account were $191,653,961. Working capital was $998,574, excluding franchise tax payable that could be paid from trust interest.
- Cash flow: Net cash used in operating activities was $662,393; net cash used in investing activities was $191,672,500; and net cash provided by financing activities was $193,076,121.
- Liabilities and debt: Total liabilities were $7,322,533, including $7,216,022 of warrant liabilities. The company reported no long-term debt, lease obligations or outstanding working-capital loans.
- IPO funding: The IPO raised $189,750,000 gross, and private placement warrants raised $7,347,500. After offering costs, reported net proceeds were $193,037,877; $191,647,500 was deposited into the trust account. Public shares are classified as temporary equity and redeemable for approximately $10.10 per share, subject to the filing’s conditions.
Changes versus prior comparable period
No prior-year comparable operating period exists because NorthView was formed in 2021. The filing reports results from inception rather than a full fiscal year of operations.
Outlook, risks and unusual items
- Management believed available working capital and borrowing capacity would meet needs through the earlier of a business combination or one year from the filing. It expected to use funds for target search, due diligence, travel and transaction costs; it cautioned that completing a business combination was not assured.
- The company had 15 months from the December 2021 IPO closing to complete a business combination, with up to two three-month extensions to 21 months if the sponsor deposits $1,897,500 per extension. If no combination is completed within the permitted period, public shares are to be redeemed and rights and warrants expire worthless.
- There is no earnings or revenue guidance. The main financial reporting volatility is the fair-value remeasurement of warrants, classified as liabilities; the resulting $597,567 gain contributed substantially to reported net income and is not operating income.
- Key risks include failing to find or complete a suitable transaction before the deadline; competition for targets; redemptions reducing cash available at closing; limited cash outside the trust; potential need for financing; sponsor and management conflicts of interest; and possible creditor claims against trust funds. COVID-19 and Russia-Ukraine-related market disruption were also identified as potential impediments.
- The company reported effective disclosure controls as of December 31, 2021. It did not include management’s internal-control assessment or auditor attestation, citing the transition period for newly public companies. The financial statements received an unqualified audit opinion; the auditor did not opine on internal-control effectiveness.
- No pending or contemplated litigation was reported. The company disclosed related-party administrative fees of $5,000 per month and reimbursement of certain sponsor, officer and director expenses without a stated cap.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-K is for NorthView Acquisition Corp., not Profusa, Inc.
- Review the audited financial statements and notes for trust-account balances, redemption terms, and warrant-liability valuation assumptions.
- Track the business-combination deadline, any sponsor-funded extensions, and whether a target or financing is announced.
- Assess redemption levels, transaction cash requirements, dilution from rights and warrants, and the $6,986,250 marketing fee payable if a business combination closes.
- Review related-party conflicts, expense reimbursements, sponsor indemnity capacity, and the risk that creditor claims or liquidation could reduce public-stockholder distributions.